Intellia Therapeutics
CompanyUnited StatesFounded 2014
Intellia Therapeutics develops 2 assets, the furthest in phase 3 (NTLA-2001 in familial amyloidosis). Mostly gene editing acting on TTR; based in the United States, founded in 2014.
- 2
- Assets
- Furthest stage
- Phase 3
- Raised
- $85M
- 4
- Trials
- 5
- Signals
Pipeline
2CRISPR-mediated disruption of hepatic TTR reduces transthyretin production and subsequent amyloid deposition.
Phase 3, Gene editing, TTR, familial amyloidosis, hereditary amyloidosis
Disrupts KLKB1 in liver cells to reduce plasma kallikrein production.
Stage not known, Gene editing
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials4
- Funding rounds and grants2
- Deals2
- Signals6
- Similar companies6